Published in Hepatology on May 20, 1987
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92
Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis (1998) 1.69
The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis (2011) 1.17
A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals. J Clin Pathol (2000) 1.00
New advances in hepatocellular carcinoma. World J Hepatol (2016) 0.91
DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol (2009) 0.87
Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S. Public Health Rep (2008) 0.79
Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses. PLoS One (2014) 0.76
Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state". Hepatol Int (2007) 0.76
Acute delta hepatitis during treatment with adenosine arabinoside monophosphate with resolution of the HBsAg carrier state. West J Med (1990) 0.75
Model of life expectancy of chronic hepatitis B carriers in an endemic region. J Epidemiol (2009) 0.75
The war on cancer: a report from the front lines. Proc (Bayl Univ Med Cent) (2006) 0.75
Should chronic HBV infected patients with normal ALT treated: debate. Hepatol Int (2008) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med (1993) 6.61
Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther (2013) 3.59
Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology (1997) 3.52
Diversity of cytokeratins. Differentiation specific expression of cytokeratin polypeptides in epithelial cells and tissues. J Mol Biol (1981) 3.37
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology (2000) 2.65
Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut (2006) 2.53
Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology (1992) 2.48
Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet (2001) 2.40
Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat (2003) 2.33
Differentiation-related patterns of expression of proteins of intermediate-size filaments in tissues and cultured cells. Cold Spring Harb Symp Quant Biol (1982) 2.32
Biochemical and immunological identification of cytokeratin proteins present in hepatocytes of mammalian liver tissue. Exp Cell Res (1981) 2.22
Atypical ductular proliferation and its inhibition by transforming growth factor beta1 in the 3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholic liver disease. Lab Invest (1999) 2.16
Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther (2013) 2.12
ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr (2006) 2.11
Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther (2013) 2.04
Postcremation diagnosis from an electric shaver. Lancet (2001) 2.02
Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology (2001) 1.92
Members of the glutathione S-transferase gene family are antigens in autoimmune hepatitis. Gastroenterology (1998) 1.91
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol (2010) 1.76
Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut (2003) 1.76
Carcinoembryonic antigen (CEA) in gastrointestinal and extragastrointestinal tumors and its relationship to tumor-cell differentiation. Int J Cancer (1972) 1.75
Primary gastrointestinal non-Hodgkin's lymphomas. A retrospective clinicopathologic study of 150 cases. Cancer (1985) 1.67
Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction. Ann Intern Med (1997) 1.64
Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol (1991) 1.62
Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology (1998) 1.62
Energy metabolism in acute and chronic renal failure. Am J Clin Nutr (1990) 1.60
Differences of expression of cytoskeletal proteins in cultured rat hepatocytes and hepatoma cells. Exp Cell Res (1981) 1.51
Wilson disease in two consecutive generations: an exceptional family. Am J Gastroenterol (2001) 1.50
Occurrence and immunolocalization of plectin in tissues. J Cell Biol (1983) 1.47
Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut (2001) 1.45
Immunocytochemical identification of epithelium-derived human tumors with antibodies to desmosomal plaque proteins. Proc Natl Acad Sci U S A (1983) 1.44
Beneficial effect of pharmacological modulation of the GABAA-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. Hepatology (1991) 1.41
ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr (1997) 1.40
[Hepatitis B and C: incidence and regional distribution of hospitalizations in Austria]. Wien Klin Wochenschr (2000) 1.40
Ultrastructural, biochemical, and immunologic characterization of Mallory bodies in livers of griseofulvin-treated mice. Fimbriated rods of filaments containing prekeratin-like polypeptides. Lab Invest (1979) 1.36
Helicobacter pylori reinfection with identical organisms: transmission by the patients' spouses. Gut (1995) 1.36
Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). World J Gastroenterol (2001) 1.35
High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol (2001) 1.33
Formation and involution of Mallory bodies ("alcoholic hyalin") in murine and human liver revealed by immunofluorescence microscopy with antibodies to prekeratin. Proc Natl Acad Sci U S A (1979) 1.33
Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology (2001) 1.32
Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol (1989) 1.30
Biochemical and immunocytochemical analysis of the intermediate filament cytoskeleton in human hepatocellular carcinomas and in hepatic neoplastic nodules of mice. Lab Invest (1982) 1.27
Has total bowel rest a beneficial effect in the treatment of Crohn's disease? Clin Nutr (1983) 1.25
Hepatocellular hyalin in cholestasis and cirrhosis: its diagnostic significance. Gastroenterology (1973) 1.23
A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer (1995) 1.22
Pronase pretreatment of tissue sections enhances sensitivity of the unlabelled antibody-enzyme (PAP) technique. J Immunol Methods (1977) 1.22
Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer (2000) 1.22
Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol (2001) 1.21
Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies. Am J Pathol (2000) 1.21
Mallory-Denk-bodies: lessons from keratin-containing hepatic inclusion bodies. Biochim Biophys Acta (2008) 1.17
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol (2012) 1.17
Proteins of intermediate filaments. An immunohistochemical and biochemical approach to the classification of soft tissue tumors. Am J Pathol (1983) 1.16
Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch (2004) 1.16
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol (2008) 1.14
Hepatocyte cytokeratins are hyperphosphorylated at multiple sites in human alcoholic hepatitis and in a mallory body mouse model. Am J Pathol (2000) 1.14
Bone disease in vitamin D-deficient patients with Crohn's disease. Dig Dis Sci (1989) 1.11
Keratin-like proteins in normal and neoplastic cells of human and rat mammary gland as revealed by immunofluorescence microscopy. Differentiation (1981) 1.10
Prevalence and clinical importance of hypertransaminasaemia in coeliac disease. Eur J Gastroenterol Hepatol (1999) 1.10
The Genome Austria Tissue Bank (GATiB). Pathobiology (2007) 1.09
Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther (2006) 1.09
The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology (1999) 1.08
Letter: comparing scoring systems and outcome of patients admitted to a liver intensive care unit with severe variceal bleeding. Aliment Pharmacol Ther (2014) 1.07
High molecular weight component of Mallory bodies detected by a monoclonal antibody. Lab Invest (1990) 1.06
Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood (2000) 1.06
Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: characterization of an improved model and study of amino acid-ergic neurotransmission. Hepatology (1989) 1.06
Kinetics of specific IgG antibodies for monitoring the effect of anti-Helicobacter pylori chemotherapy. J Infect Dis (1993) 1.05
Chemotherapy for the treatment of patients with primary high grade gastric B-cell lymphoma of modified Ann Arbor Stages IE and IIE. Cancer (2000) 1.03
Immunohistochemical demonstration of cytokeratins in endocrine cells of the human pituitary gland and in pituitary adenomas. Virchows Arch A Pathol Anat Histopathol (1984) 1.03
Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J Neurol (1991) 1.02
High amount of epsilon-(gamma-glutamyl)lysine cross-links in Mallory bodies. Lab Invest (1992) 1.02
Hepatocellar hyalin (Mallory bodies) in long term griseofulvin-treated mice: a new experimental model for the study of hyalin formation. Lab Invest (1975) 1.01
Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent. Am J Pathol (1999) 1.01
Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J Clin Virol (2010) 1.01
Long-term prognosis for colon cancer related to consistent radical surgery: multivariate analysis of clinical, surgical, and pathologic variables. World J Surg (2000) 1.01
Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology (1998) 1.00
Acidic colonic microclimate--possible reason for false negative hydrogen breath tests. Gut (1988) 1.00
Mechanism of cholestasis. 4. Structural and biochemical changes in the liver and serum in rats after bile duct ligation. Gastroenterology (1971) 1.00
Change of cytokeratin organization during development of Mallory bodies as revealed by a monoclonal antibody. Lab Invest (1986) 1.00
Intermediate filament cytoskeleton of the liver in health and disease. Histochem Cell Biol (2008) 0.99
Dental and periodontal disease in patients with cirrhosis--role of etiology of liver disease. J Hepatol (1995) 0.99
Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology (1996) 0.99
The distribution of intermediate filament proteins, actin and desmoplakins in human placental tissue as revealed by polyclonal and monoclonal antibodies. Placenta (1989) 0.98
Improvement of hepatic encephalopathy treated with flumazenil. Lancet (1988) 0.98
Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut (2005) 0.98
The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson's disease. Brain (2000) 0.98
Experimental induction of hepatocellular hyalin (Mallory bodies) in mice by griseofulvin treatment. 1. Light microscopic observation. Lab Invest (1976) 0.98
Histopathology of portal hypertension: a practical guideline. Histopathology (2003) 0.98
Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther (2012) 0.97
Peripheral T-cell lymphomas of the intestine. Am J Pathol (1992) 0.97
New immunocytochemical observations with diagnostic significance in cutaneous neuroendocrine carcinoma. Am J Dermatopathol (1984) 0.97
Screening for celiac disease: a prospective study on the value of noninvasive tests. Am J Gastroenterol (1995) 0.97
Predominance of the HLA-H Cys282Tyr mutation in Austrian patients with genetic haemochromatosis. J Hepatol (1997) 0.96